Cargando…

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

Biomarkers to identify patients without benefit from adding everolimus to endocrine treatment in metastatic breast cancer (MBC) are needed. We report the results of the Pearl trial conducted in five Belgian centers assessing (18)F-FDG-PET/CT non-response (n = 45) and ctDNA detection (n = 46) after 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gombos, Andrea, Venet, David, Ameye, Lieveke, Vuylsteke, Peter, Neven, Patrick, Richard, Vincent, Duhoux, Francois P., Laes, Jean-Francois, Rothe, Françoise, Sotiriou, Christos, Paesmans, Marianne, Awada, Ahmad, Guiot, Thomas, Flamen, Patrick, Piccart-Gebhart, Martine, Ignatiadis, Michail, Gebhart, Géraldine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455671/ https://www.ncbi.nlm.nih.gov/pubmed/34548493 http://dx.doi.org/10.1038/s41523-021-00331-8

Ejemplares similares

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2022)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
por: Bareche, Y, et al.
Publicado: (2018)

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2016)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor
por: Vandeputte, Caroline, et al.
Publicado: (2018)

Targeting immune checkpoints in breast cancer: an update of early results
por: Solinas, Cinzia, et al.
Publicado: (2017)

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
por: de Azambuja, E, et al.
Publicado: (2007)

Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials
por: Charette, Nicolas, et al.
Publicado: (2019)

New generation of breast cancer clinical trials implementing molecular profiling
por: Zardavas, Dimitrios, et al.
Publicado: (2016)

N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by (89)Zr-Trastuzumab and (18)F-FDG PET imaging
por: Wimana, Zéna, et al.
Publicado: (2017)

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
por: Buisseret, Laurence, et al.
Publicado: (2023)

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
por: Rossari, José R., et al.
Publicado: (2012)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer
por: Hendlisz, Alain, et al.
Publicado: (2015)

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial
por: De Caluwé, Alex, et al.
Publicado: (2021)

Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer
por: El Hachem, Georges, et al.
Publicado: (2019)

Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol
por: Hendlisz, Alain, et al.
Publicado: (2015)

Are Intensive Cares Worthwhile for Breast Cancer Patients: The Experience of an Oncological ICU
por: Destrebecq, Virginie, et al.
Publicado: (2016)

The current use and attitudes towards tumor genome sequencing in breast cancer
por: Gingras, I., et al.
Publicado: (2016)

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
por: Sonnenblick, Amir, et al.
Publicado: (2015)

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial
por: Sonnenblick, Amir, et al.
Publicado: (2015)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer
por: Woff, Erwin, et al.
Publicado: (2016)

Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study
por: Deleporte, Amelie, et al.
Publicado: (2014)

pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation
por: Sonnenblick, Amir, et al.
Publicado: (2019)

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
por: Mileva, Magdalena, et al.
Publicado: (2020)

How I treat endocrine-dependent metastatic breast cancer
por: Gombos, A., et al.
Publicado: (2023)

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients
por: Lambertini, Matteo, et al.
Publicado: (2016)

Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis
por: Rothé, Françoise, et al.
Publicado: (2022)

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis
por: Martins-Branco, Diogo, et al.
Publicado: (2022)

Adenoid cystic carcinoma of the breast – an aggressive presentation with pulmonary, kidney, and brain metastases: a case report
por: Mhamdi, Hasnae Alaoui, et al.
Publicado: (2017)

Everolimus in acute kidney injury in a patient with breast cancer: a case report
por: Donders, Francesca, et al.
Publicado: (2014)

Heat conduction and mass diffusion
por: Gebhart, Benjamin
Publicado: (1993)

Heat conduction and mass diffusion
por: Gebhart, Benjamin
Publicado: (1993)

Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer
por: Rothé, Françoise, et al.
Publicado: (2011)

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study
por: Hendlisz, Alain, et al.
Publicado: (2013)

Two Years’ Experience with a Dental Program
por: Gebhart, John C.
Publicado: (1922)

Immunotherapy in breast cancer: an overview of current strategies and perspectives
por: Debien, Véronique, et al.
Publicado: (2023)

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations
por: Nguyen, Bastien, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_32a19rt5dc60fnj371tqhbjqtv